An AI system may spot pancreatic cancer long before it becomes visible. A new artificial intelligence system called REDMOD ...
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced its long-term data titled ...
The FDA has approved expanded access to Revolution Medicines’ investigational drug daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma, following striking ...
An AI model (REDMOD) can pick up the very early subtle tissue changes of pancreatic ductal adenocarcinoma, the most common ...
Pancreatic ductal adenocarcinoma is one of the deadliest cancer types, with a five-year survival rate of 13%. There are only ...
Researchers have developed REDMOD, an AI system that can detect stage 0 pancreatic ductal adenocarcinoma on standard CT scans up to three years before clinical diagnosis. The model identifies subtle ...
Gastroesophageal adenocarcinoma (GEA), a cancer prevalent in the esophagus' glandular cells or stomach's gastroesophageal junction, is on the rise due to risk factors like GERD, obesity, and smoking.
Kelly, MD, MBA, and participants discussed key considerations for biomarker testing in upper GI cancers. Biomarker status has ...
In this study, researchers aimed to examine survival outcomes with elraglusib plus chemotherapy compared to chemotherapy alone in untreated mPDAC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results